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tions on the aortic arch.1,2 Its main limitation is the time
constraint. At a brain temperature of 10°C to 15°C, 10%
to 20% of the baseline cerebral metabolic rate of oxy-
gen (CMRO2) is left and the onset of permanent injury
is delayed 40 to 50 minutes.3 Selective antegrade cere-
bral perfusion and retrograde cerebral perfusion are
other strategies used for brain protection during aortic
arch surgery. Unfortunately, not all expectations
addressed to these methods have been fulfilled, leading
to renewed interest in the search for other methods to
increase the permissible period of HCA.
A biochemical cascade in the failure of neurotrans-
mitters has been demonstrated to be a crucial link in the
pathogenesis of ischemic brain injury.4-6 Glutamate
accumulates in the intercellular space and acts as a neu-
rotoxic substance. It opens calcium channels, leading to
an influx of calcium, which starts the catastrophic cas-
cade that eventually leads to neuronal autodigestion and
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cell death.6 Better understanding of these biochemical
mechanisms of cerebral damage has opened new thera-
peutic windows to improve brain protection when nor-
mal antegrade cerebral perfusion is compromised.
Lamotrigine (3,5-diamino-6-[2,3-dichlorophenyl]-
1,2,4-triazine) is an Na+ channel blocker used clinical-
ly as an antiepileptic drug. It has few side effects and
can be administered orally. In view of the interaction of
lamotrigine with Na+ channels and its ability to pene-
trate the blood-brain barrier, interest has been focused
on its neuroprotective properties. In an experimental
study of global cerebral ischemia in a rabbit model,
glutamate concentrations in animals receiving lamo-
trigine were significantly lower than in the controls.7 A
study in gerbils showed a neuroprotective effect of lam-
otrigine after global ischemia.8
The aim of this study was to test the neuroprotective
efficacy of lamotrigine during HCA in a chronic
porcine model.
Materials and methods
Sixteen female juvenile (8- to 10-week-old) pigs of a native
stock, weighing 21 to 27 kg, were randomly assigned to
receive either lamotrigine or saline solution before a 75-
minute period of HCA at 20°C.
Preoperative management. All animals received humane
care in accordance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal
Resources and published by the National Institutes of Health
(NIH publication No. 85-23, revised 1985). The study was
approved by the Research Animal Care and Use Committee
of the University of Oulu.
Drug administration. An isethionate (2-hydroxyethane-
sulfonate) salt of lamotrigine (3,5-diamino-6-[2,3-
dichlorophenyl]-1,2,4-triazine) was diluted in saline solution
to obtain a solution containing lamotrigine at 50 mg/mL, and
this was packed in 10-mL ampules in the pharmaceutical lab-
oratory of our institution. Saline placebo ampules were pre-
pared similarly. A dose of 20 mg/kg was measured and dilut-
ed to 50 mL in saline solution. This volume was given
intravenously over a period of 20 minutes, starting 2 hours
before HCA. Randomization was carried out by the chemist
in the pharmaceutical laboratory, and the codes were broken
after the entire series of experiments were accomplished.
Therefore, all observers in every data recording point were
unaware of whether the animal was a lamotrigine subject or a
control subject.
Anesthesia and hemodynamic monitoring. Anesthesia
was induced with ketamine hydrochloride (10 mg/kg intra-
muscularly) and midazolam (1 mg/kg intramuscularly), and
muscular paralysis was maintained with pancuronium bro-
mide (0.1 mg/kg intravenously). After endotracheal intuba-
tion, the animals received positive-pressure ventilation with
100% oxygen; anesthesia was maintained with isoflurane
(1.1%-1.2%). An arterial catheter was positioned in the left
femoral artery. Thermodilution catheters (CritiCath, 7F;
Ohmeda GmbH & Co, Erlangen, Germany) were placed in
the femoral vein to allow blood sampling, pressure monitor-
ing in the pulmonary artery, and the recording of cardiac out-
put. An intracranial temperature probe was placed through a
drill hole in the epidural space. The drill hole was positioned
1 cm to the right of a sagittal joint above a parietal line. Other
temperature probes were placed in the esophagus and rectum,
and a 10F catheter was placed in the urinary bladder to mon-
itor urine output.
Electroencephalographic monitoring. Cortical electrical
activity, the electroencephalogram (EEG), was registered
from 4 stainless steel screw electrodes (5 mm in diameter)
implanted in the skull over the parietal and frontal areas of
the cortex. These electrodes were referenced to a frontal
screw electrode, which together with a ground screw elec-
trode was implanted over the frontal sinuses. A digital EEG
recorder (Nervus; Reykjavik, Iceland) and an amplifier
(Magnus EEG 32/8; Reykjavik, Iceland) were used in record-
ing, with sampling frequency 1024 Hz and bandwidth 0.03 to
256 Hz. Continuous baseline EEG was recorded over a peri-
od of 10 minutes half an hour after induction of anesthesia.
Isoflurane anesthesia was adjusted so that the EEG showed a
burst-suppression pattern, that is, high-amplitude EEG bursts
interrupted by low-amplitude suppressions. Isoflurane con-
centration in inflow gas was adjusted to level to 1.1% to 1.2%
throughout recording. Approximately 90 minutes from the
start of drug administration, the second EEG was recorded at
normothermia. A continuous EEG was recorded from the
beginning of rewarming until 41⁄2 hours. The bursts disap-
peared as a result of HCA. After rewarming, the bursts
became longer and increased in number and duration,
approaching the baseline level in the best case. The total
duration of burst measurement interval was calculated at
baseline and then repeatedly during rewarming. The ratio of
burst durations at these points, divided by the duration at
baseline, was used as a simple quantitative measure of EEG
recovery.
Cardiopulmonary bypass. Through a right thoracotomy
in the fourth intercostal space, the right thoracic artery was
ligated and the heart and great vessels were exposed. A mem-
brane oxygenator (Midiflow D 705; Dideco, Mirandola,
Italy) was primed with 1 L of Ringer acetate and heparin
(5000 IU). After heparinization (300 IU/kg), the ascending
aorta was cannulated with a 16F arterial cannula and the right
atrial appendage with a single 24F atrial cannula.
Nonpulsatile cardiopulmonary bypass (CPB) was initiated at
a flow rate of 100 mL/kg per minute and the flow was adjust-
ed to maintain a perfusion pressure of 50 mm Hg. A 12F
intracardiac sump cannula was positioned in the left ventricle
for decompression of the left side of the heart during CPB. A
heat exchanger was used for core cooling. The pH was main-
tained, by alpha-stat principles, at 7.40 ± 0.05 with an arteri-
al PCO2 of 4.0 to 5.0 kPa, uncorrected for temperature. All
measurements were performed at 37°C.
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A cooling period of 60 minutes was carried out to attain a
rectal temperature of 20°C. The ascending aorta was cross-
clamped. Cardiac arrest was induced by injecting potassium
chloride (1 mEq/kg) via the aortic cannula, and topical car-
diac cooling was maintained throughout the aortic cross-
clamp period.
Experimental protocol. After cooling to 20°C, a 75-
minute interval of HCA with the head packed in ice was con-
ducted. After this, CPB rewarming was started. The left ven-
tricular vent cannula was removed. Weaning from CPB
occurred approximately 60 minutes after the start of rewarm-
ing with administration of furosemide (40 mg), mannitol
(15.0 g), methylprednisolone (80 mg), and lidocaine (40-150
mg). Cardiac support was provided by dopamine. The ani-
mals were kept in isoflurane anesthesia until the following
morning, extubated, and moved into a recovery room.
During the experiments, hemodynamic and metabolic mea-
surements were recorded at 5 time points as follows: at base-
line; at the end of cooling (at 20°C); during rewarming (at
30°C); and 2 and 4 hours after the start of rewarming.
Postoperative evaluation. Postoperatively, all the animals
were evaluated daily by an experienced observer (J.R.) who
was blinded to the treatment assignment. The examiner used
a species-specific quantitative behavioral score as reported
earlier.9 The assessment quantified mental status (0 =
comatose, 1 = stuporous, 2 = depressed, 3 = normal), appetite
(0 = refuses liquids, 1 = refuses solids, 2 = decreased, 3 = nor-
mal), and motor function (0 = unable to stand, 1 = unable to
walk, 2 = unsteady gait, 3 = normal). Numeric summing of
these functions provides a final score: the maximum (score of
9) reflects apparently normal neurologic function, whereas
lower values indicate substantial neurologic damage. A score
of 8 means that the animals were able to stand unassisted and
were likely to recover fully.
Each surviving animal was electively put to death on day
7 after the operation. The entire brain was immediately har-
vested, weighed, and taken for subsequent histologic
analysis.
Histopathologic analysis. During autopsy the brain was
excised immediately and the hemispheres were separated.
One half was immersed in 10% neutral formalin and allowed
to fix for 2 weeks en bloc. Coronal samples 3-mm thick were
sliced from the frontal lobe, thalamus (including the adjacent
cortex), and hippocampus (including the adjacent brain stem
and temporal cortex), and sagittal samples were sliced from
the posterior brain stem (medulla oblongata and pons) and
cerebellum. The pieces were fixed in fresh formalin for
another week. After fixation, the samples were processed as
follows: rinsing in water for 20 minutes and immersion in
70% ethanol for 2 hours, in 94% ethanol for 4 hours, and in
absolute ethanol for 9 hours. Thereafter, the pieces were kept
1 hour in an absolute ethanol-xylene mixture, 4 hours in
xylene, and embedded in warm paraffin wax for 6 hours. The
samples were sectioned at 6 µm and stained with hema-
toxylin-eosin. The sections of the brain samples from each
animal were screened by a single experienced senior pathol-
ogist (J.H.) unaware of the experimental design and the iden-
tity and fate of individual animals. Each section was careful-
ly investigated for the presence or absence of any ischemic or
other damage.
Visual estimation of the injuries in the sampled regions was
as follows: 0 = no morphologic damage identified, 1 = edema
and/or occasional dark neurons, 2 = numerous dark neurons
(often also shrunk) and eosinophilic or dark/shrunken cere-
bellar Purkinje cells or hemorrhages, and 3 = clearly infarc-
tive foci with neoformation of capillaries, presence of
macrophages, and a glial reaction.
So that semiquantitative comparisons could be made
between the animals, a total histologic score was calculated
by adding all the regional scores. A score more than 4 means
that the animal had a distinct brain injury.
Serum S-100β. Concentrations of serum S-100β were
determined in mixed venous blood samples by means of a
luminescence immunoassay kit (Sangtec-100, LIA-mat;
Sangtec Medical AB, Bromma, Sweden). Serum S-100β pro-
tein levels were measured preoperatively and 2 hours, 4
hours, 7 hours, and 20 hours after the start of rewarming.
Other measurements. Systemic arterial and venous blood
samples were obtained to determine pH, PO2, PCO2, oxygen
saturation, oxygen content, hematocrit value, and hemoglo-
bin and glucose concentrations (Ciba-Corning 288 Blood Gas
System; Ciba-Corning Diagnostic Corp, Medfield, Mass).
Lactate was analyzed with a YSI 1500 analyzer (Yellow
Springs Instrument Co, Yellow Springs, Ohio). Hemo-
dynamics, temperatures, and respiratory gases were moni-
tored by the Datex AS/3 anesthesia monitor (Datex Inc,
Espoo, Finland).
Statistical analysis. Summary statistics for continuous or
ordinal variables are expressed as the median with interquar-
tile range (IQR, 25th and 75th percentile) or means with stan-
dard deviation (SD). In the figures, values are shown as medi-
ans with IQR. The t test assumptions (normality or equality
of variances) were checked first and a corresponding signifi-
cance test, parametric (t test), or nonparametric test (Mann-
Whitney U test) was used. One-tailed P values were reported
where appropriate. Longitudinal analysis was performed by
2-way analysis of variance. Also, visual evaluation of time
series was done to determine interactions between time and
protocol. Comparison between each time point and baseline
(reference category) was performed by paired samples t test
or Wilcoxon matched pairs signed rank test. Again, normali-
ty assumptions were tested first. Significance levels are
reported for comparisons with P < .05. However, the levels of
statistical significance should be interpreted with caution,
given the large number of statistical tests performed.
Analyses were performed with a standard commercially
available statistical program (SPSS version 8.0; SPSS Inc,
Chicago, Ill).
Results
Physiologic data 
Comparability of experimental groups. The mean (±
SD) weight of the animals in the lamotrigine group was
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23 ± 1 kg and in the placebo group 24 ± 2 kg (P > .2).
The mean (± SD) CPB cooling time in the lamotrigine
group was 61 ± 3 minutes and in the placebo group 
62 ± 4 minutes (P > .2). Rewarming time in the lamotri-
gine group was 68 ± 6 minutes and in the placebo group
70 ± 12 minutes (P > .2). Temperatures during the
experimental period did not differ between the groups.
Hemodynamic data. All animals were in stable condi-
tion before, during, and after CPB, although mean arteri-
al pressure remained below baseline levels after the peri-
od of HCA. No significant differences in hemodynamic
measurements between the groups were found (Table I).
Blood gas and hematocrit measurements. Blood gas
and hematocrit measurements are shown in Table I.
The lamotrigine group showed a decrease in pH at the
end of cooling and during rewarming when 30°C was
reached, compared with baseline (P < .05). Both
groups showed decreased pH at 2 and 4 hours after the
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Table I. Hemodynamic data, blood gases, and hematocrit values in 16 pigs undergoing either lamotrigine 
(20 mg/kg) or placebo administration before a 75-minute period of HCA
Baseline End of CPB After start of rewarming
Group N (37°C) cooling (20°C) (30°C) Two hours Four hours
MAP (mm Hg)
Lamotrigine 8 74 (68-75) 54 (50-57)‡ 54 (50-57)‡ 55 (53-57)‡ 62 (53-67)*
Placebo 8 77 (76-81) 56 (54-58)‡ 56 (52-59)‡ 59 (49-70)* 70 (67-73)*
Cardiac output/CPB flow (L/min)
Lamotrigine 8 3.5 (3.2-4.0) 2.4 (2.2-3.0) 2.5 (2.4-2.5) 4.4 (4.1-5.0) 3.8 (3.4-4.0)
Placebo 8 3.6 (3.5-4.5) 2.5 (2.1-3.0) 2.6 (2.4-2.7) 3.9 (3.7-4.6) 3.1 (2.7-3.3)*
Arterial pH
Lamotrigine 8 7.49 (7.46-7.51) 7.40 (7.32-7.46)* 7.41 (7.38-7.46)* 7.30 (7.27-7.33)‡ 7.42 (7.37-7.44)†
Placebo 8 7.47 (7.45-7.50) 7.43 (7.36-7.48) 7.49 (7.42-7.51) 7.31 (7.29-7.32)‡ 7.41 (7.35-7.43)*
Arterial PCO2 (mm Hg)
Lamotrigine 8 38.9 (37.2-42.5) 41.5 (37.0-45.1) 27.7 (25.0-29.3)‡ 46.6 (40.7-47.9)* 46.4 (41.6-48.3)*
Placebo 8 42.2 (38.4-44.6) 39.5 (33.5-48.2) 24.8 (23.3-26.6)‡ 46.0 (45.2-54.0)* 46.5 (44.9-49.7)*
Hematocrit
Lamotrigine 8 25.2 (24.6-26.0) 16.7 (15.8-17.8)‡ 18.5 (17.7-19.4)‡ 24.9 (22.7-26.4) 25.8 (23.8-27.7)
Placebo 8 29.1 (26.5-29.3) 18.5 (16.5-19.9)‡ 18.2 (17.8-20.6)‡ 25.0 (22.9-25.3) 26.7 (25.2-27.1)
MAP, Mean arterial pressure; CPB, cardiopulmonary bypass; PCO2, carbon dioxide tension. Values are shown as medians with IQR.
*P < .05 compared with baseline. 
†P < .01 compared with baseline. 
‡P < .001 compared with baseline.
Table II. Venous lactate levels, oxygen extraction, and oxygen consumption during the experiment in 16 pigs
undergoing either lamotrigine (20 mg/kg) or placebo administration before a 75-minute period of HCA
Baseline End of  CPB After start of rewarming
Group N (37°C) cooling (20°C) (30°C) Two hours Four hours
Venous lactate (mmol/L)
Lamotrigine 8 1.05 (1.04-1.42) 2.14 (2.02-2.43)† 7.16 (6.56-7.45)‡ 5.60 (5.17-6.49)‡ 2.65 (2.31-3.06)†
Placebo 8 0.98 (0.75-1.07) 1.84 (1.49-1.97)† 6.96 (5.92-7.23)‡ 6.07 (3.31-8.11)‡ 1.82 (1.09-4.21)*
Oxygen extraction (mL/dL)
Lamotrigine 8 2.7 (2.5-3.2) 1.5 (0.7-2.2)‡ 2.7 (2.7-3.0) 2.3 (2.2-2.9) 2.7 (2.7-2.8)
Placebo 8 2.6 (1.7-2.8) 1.4 (1.2-1.7)‡ 3.3 (3.1-3.4) 2.8 (2.8-3.6) 3.7 (3.4-4.2)*
P = .001 P = .03 P = .01
Oxygen consumption (mL/min)
Lamotrigine 8 100.3 (84.4-109.8) 33.0 (19.5-47.8)‡ 70.0 (68.2-76.2) 103.7 (95.7-123.5) 105.6 (92.3-111.4)
Placebo 8 80.3 (68.1-113.4) 33.0 (28.4-41.6)‡ 81.5 (75.8-87.5) 128.2 (113.8-139.0)* 108.8 (98.0-143.4)
P = .04
For abbreviations see Table I. Values are shown as medians with IQRs.
*P < .05 compared with baseline. 
†P < .01 compared with baseline. 
‡P < .001 compared with baseline.
start of rewarming when compared with baseline 
(P < .05). There were no significant differences
between the groups. Arterial PCO2 was higher in both
groups 2 and 4 hours after the start of rewarming com-
pared with baseline (P < .05).
Metabolic data. Venous lactate levels increased dur-
ing cooling, especially after intervention, in both
groups. Oxygen extraction was higher after the start of
rewarming in the placebo group than in the lamotrigine
group. Oxygen consumption was higher in the placebo
group when 30°C was reached during rewarming com-
pared with the lamotrigine group (P = .04) (Table II).
EEG. There was no significant difference between
the groups at recording points before and after drug
administration or within the groups. At the baseline,
median (IQR) of burst-suppression ratio, that is, high-
amplitude EEG bursts interrupted by low-amplitude
suppressions, was 0.29 (0.22-0.49) in the lamotrigine
group and 0.45 (0.35-0.60) in the placebo group (P =
.29). After drug administration, these values were 0.26
(0.19-0.51) and 0.43 (0.36-0.68) (P = .07), respective-
ly. When EEG activity after drug administration was
compared with baseline, P value was .47 in the lamo-
trigine group and .15 in the placebo group. The percent
of EEG burst recovery compared with baseline is
shown at Fig 1. This recovery was found to be higher
in the lamotrigine group, the median being 40% com-
pared with 17% in the placebo group at 4 hours (P =
.02) and 80% compared with 20% at 41⁄2 hours after the
start of rewarming (P = .01).
Morbidity and mortality. All animals were in stable
condition during the surgical procedures and survived
to at least the first postoperative day. Eleven of the 16
animals (69%) survived 7 days after the operation and
were electively put to death. In the lamotrigine group,
6 of 8 (75%) animals survived 7 days compared with 5
of 8 (63%) in the placebo group (P > .2) (Table III).
During the autopsy of the animals that died on the first
postoperative day, severe lung congestion (lamotrigine
group, n = 1) and acute myocardial infarction (placebo
group, n = 1) were the causes of death. Three animals
(lamotrigine, n = 1; placebo, n = 2) died of severe brain
damage and were not able to breath. During the autop-
sy, significant brain edema, especially in the cerebel-
lum and brain stem, was detected.
Behavioral outcome. The results of behavioral scor-
ing for both groups are shown in Fig 2. A score of 8 or
9 indicates essentially complete neurologic recovery.
Animals that died early were given a score of 0 begin-
ning at the time of death. Complete behavioral recov-
ery was seen in 5 of 8 (63%) animals after lamotrigine
administration, compared with 1 of 8 (13%) animals in
the placebo group (P = .02). Among the animals that
survived for 7 days, the median behavioral score was
higher in the lamotrigine group (8) than in the control
group (7) (P = .02).
Histopathologic results. The median of total
histopathologic score in the lamotrigine group was 5.5
and in the placebo group 7.5 (P = .06) (Fig 3). The
median histopathologic score in the hippocampus was
lower in the lamotrigine group (0) than in the placebo
group (0.5), although this difference was not statistical-
ly significant (P = .09) (Table III).
S-100β. An average 3-fold increase in S-100β levels
in both groups compared with baseline was seen 2
hours after the start of rewarming (P = .01). The medi-
an S-100β concentration remained at a lower level in
the lamotrigine group, being statistically significant 20
hours after the start of rewarming (0.1 µg/L vs 0.03
µg/L; P = .01) (Fig 4).
Discussion
The results of this study indicate that lamotrigine
may improve cerebral outcome after a prolonged peri-
od of HCA. The better outcome was seen in terms of
neurophysiologic, behavioral, S-100β, and histopatho-
logic data. The results confirm those of previous stud-
ies suggesting that lamotrigine has neuroprotective
effects.8 This study is the first to report a possible ben-
efit of lamotrigine during HCA.
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Fig 1. Medians with IQRs of total EEG burst ratios (relative
to baseline) of 16 pigs undergoing either lamotrigine or
placebo administration before a 75-minute period of HCA.
EEG bursts recovered significantly better in the lamotrigine
group 4 hours after the start of rewarming than in the place-
bo group (P < .05).
Hypothermia is known to produce a significant
decrease in CMRO2, increasing the permissible period
of HCA.10 However, even in deep hypothermia (10°-
15°C), a significant degree of CMRO2 remains and the
duration of safe HCA is limited to 40 to 50 minutes.3
Previous studies suggest that energy failure itself is not
particularly toxic to neurons.6 What makes it neurotox-
ic is subsequent failure of neurotransmitter transport.
The ischemic injury begins with depolarization of the
presynaptic membrane mediated by the metabolic fail-
ure of voltage-sensitive Na+ channels that carry electri-
cal messages to the synapse. Depolarization leads to
secretion of neurotransmitters (glutamate). In the nor-
mal environment, after release into the intercellular
space, glutamate is rapidly converted to glutamine and
re-enters the neuron ready to be used for the next mes-
sage. Because of depletion of cellular energy during
ischemia, the high affinity of glutamate is compro-
mised. This interrupts the conversion of glutamate to
glutamine and leads to its accumulation in the intercel-
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Fig 2. Daily scores indicating behavioral recovery after interventions. A score of 8 or 9 indicates essentially com-
plete recovery, lower scores indicate substantial impairment, and 0 indicates coma or death. Behavioral scores on
day 7 after the operation among the surviving animals showed a significant difference between the groups (P = .02).
Table III.  Histopathologic scores and survival after the experiment in 16 pigs undergoing either lamotrigine (20
mg/kg) or placebo administration before a 75-minute period of HCA
Protocol Pig No. Survival (d) Cortex Thalamus Hippocampus Posterior brain stem Cerebellum Total score
Lamotrigine 1 1 2 0 0 2 0 4
2 7 1 0 0 1 1 3
3 1 2 2 0 2 0 6
4 7 0 0 0 2 2 4
5 7 3 0 0 1 1 5
6 7 3 0 0 2 1 6
7 7 3 3 1 2 2 11
8 7 2 1 1 2 1 7
Placebo 1 7 3 2 0 2 1 8
2 7 2 2 2 2 0 8
3 7 2 0 0 1 1 4
4 7 2 0 2 2 1 7
5 1 2 2 1 2 2 9
6 7 3 2 0 2 0 7
7 1 1 0 0 2 2 5
8 1 1 2 2 2 1 8
Scores: 0 = no morphologic damage; 1 = edema and/or occasional dark neurons; 2 = numerous dark neurons and eosinophilic or dark/shrunk cerebellar Purkinje cells
or hemorrhages; 3 = clearly infarctive foci.
lular space, where it acts as a potent neurotoxic sub-
stance. It opens calcium channels, leading to an influx
of calcium, which starts the catastrophic intracellular
activation of protease, lipase, and kinase C, along with
altered transcription and release of free oxygen radi-
cals, that eventually leads to neuronal autodigestion
and cell death.6
This knowledge has opened up new avenues of
research to improve current methods to protect the
brain during ischemia. If this biochemical cascade
could be blocked by a suitable antagonist, the neurons
might survive a period of depletion of oxygen and
metabolites. The most frequently studied antagonists
are the glutamate receptor blockers and Ca2+ and Na+
channel antagonists.11-13 Despite promising results in
experimental studies with various specific intervention-
al agents, most of these have turned out to be neuro-
toxic in a clinical setting, and trials have been stopped
due to side effects, such as sympatholytic effects of
SNX-111, nefrotoxicity of NBQX, and hallucinogenic
properties of MK-801.14 The reason to test lamotrigine
in the present study was that it is safely used clinically
as an antiepileptic drug. Its proposed mechanism is pre-
vention of Na+-dependent depolarization and subse-
quent neurotransmitter release.14
Lamotrigine is rapidly absorbed, and the bioavail-
ability of the oral formulation is about 98%. Peak
serum levels are reached within 3 hours. The concen-
tration of lamotrigine is the same in brain and plasma,
mean half-life being 23 to 37 hours.15 The present dose
of lamotrigine was higher than recommended in
antiepileptic medication, but this dose should also be
tolerated by human beings. Histopathologic evaluation
4 days after 5 and 15 minutes of a global ischemia in
gerbils in normothermia demonstrated neuroprotective
efficacy of lamotrigine (100 mg/kg).16 In another study
with gerbils, improved protection was demonstrated
histologically at 7 and 28 days after focal ischemia in
animals treated with lamotrigine before and after
insult.8
The survivals in the current study were 75% in the
lamotrigine group and 63% in the placebo group. In
terms of behavioral assessment, however, a better out-
come was seen in the lamotrigine group. Among the
animals that survived for 7 days, the behavioral score
was better in the lamotrigine group. The median score
of 8 in lamotrigine-treated animals indicates a mild dis-
turbance or full recovery. Control animals showed
more severe initial neurologic impairment, and only 1
control animal recovered to a score of 8.
EEG bursts recovered better in the lamotrigine group
at 4 hours after the start of rewarming than in the place-
bo group. Ischemic brain damage, surgical disconnec-
tion of cortical blocks, and several anesthetics are
known to produce burst suppression in EEG. The
effects of anesthetics and brain damage are additive.17
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Fig 3. Total histopathologic scores among 16 pigs undergo-
ing either lamotrigine or placebo administration before a 75-
minute period of HCA. The total histopathologic score was
calculated by adding the quantitative assessment of
histopathologic findings in the investigated regions of the
brain for each of the animals. The scores in the lamotrigine
group were lower than in the placebo group (P = .06).
Fig 4. S-100β levels of 16 pigs undergoing either lamotrigine
or placebo administration before a 75-minute period of HCA.
S-100β levels were lower in the lamotrigine group 20 hours
after the start of rewarming (P = .01). Two hours after the
start of rewarming, S-100β levels were higher than at base-
line (P = .03). Values are shown as medians with IQRs.
In the present study, the additive effect of ischemic
damage plus isoflurane-produced burst suppression
proved to be a sensitive measure of recovery. The bursts
are readily detected and their duration can be measured
even when EEG recordings are very low in amplitude
as a result of hypothermia, close to the noise level of
the recording system, when other quantification of
EEG recordings is questionable. The EEG recovery
was in line with other measures of brain damage, sug-
gesting that it correctly reflects the neuroprotective
effect of lamotrigine. It may also be able to accurately
pinpoint the time when lamotrigine-protected brains
are recovering better than those in the placebo group.
Our previous studies, using EEG, have also suggested
that approximately 3 hours after HCA a change in brain
electrical activity correctly distinguishes between pigs
that will have severe damage and those that will fare
better.18 Whether this kind of monitoring can be used in
a clinical setting to identify those patients in whom spe-
cial measures should be carried out for brain protection
remains to be seen.
The S-100 protein is a small dimetric cytosolic protein
that exists in various forms depending on its chain (α or
β) structure. The ββ form predominantly occurs in
astroglial and Schwann cells and the αβ form in
astroglial cells, the concentrations in other cells being
negligible. S-100 protein is involved in promoting axon-
al growth, glial proliferation, neuronal differentiation,
and calcium homeostasis.19 Increased levels of S-100
protein have been measured after cardiac operations,
stroke, and several other neurologic disorders.20,21 This
marker has been enthusiastically adopted for clinical use
by many cardiac surgeons, with the expectation that
repeated measurements could indicate brain injury post-
operatively.20 In the present study, in response to
ischemic brain insult, S-100β levels increased signifi-
cantly shortly after the start of rewarming in both of the
groups. The finding that S-100β concentrations
decreased to a lower level on day 1 after the operation in
lamotrigine-treated animals is in line with other outcome
data and supports the findings of better brain protection
in these animals compared with controls.
Our findings are supported by a recent article demon-
strating that lamotrigine has an effect on glutamate
release in the pig. The most likely mechanism leading
to improved neurologic outcome seen in the current
study after lamotrigine treatment is the inhibition of
glutamate release.22 Several differences exist in the
experimental design between these 2 studies, however,
making further comparisons difficult. The major limi-
tation in this respect is that animals were exposed to 15-
minute periods of global ischemia at normothermia in
the previous study. It must be borne in mind that
hypothermia per se is the most powerful tool to prevent
the release of neurotransmitters. The finding that lam-
otrigine did not attenuate the release of neurotransmit-
ters at the level of 20 mg/kg22 does not prove that this
cannot occur after 3-fold longer periods of ischemia at
20°C. Their finding is that no improvement in neuro-
logic parameters including EEG recovery, brain lactate,
and S-100β protein release is attenuated by the use of
an acute model. As seen from the present data, signifi-
cant differences in EEG recovery and S-100β levels
were found several hours after the start of rewarming.
Therefore, it seems especially important to remember
that laboratory studies that do not include some reliable
measures of neurologic outcome must be interpreted
with caution.
In conclusion, the present results suggest that the
Na+ channel blocker lamotrigine improves neurologic
outcome after a prolonged period of HCA.
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